Phenytoin is one of the most used antiepileptic drugs. Isoniazid, a first-line antitubercular drug, blocks the CYP2C19 enzyme, preventing phenytoin from being metabolised. Concomitant use of phenytoin and isoniazid predisposes to phenytoin toxicity. Here, we present the case of a female in her mid-30s with a known seizure disorder on phenytoin monotherapy. She was also started on antitubercular therapy, including isoniazid, after being diagnosed with pulmonary tuberculosis recently. This led to a catastrophic sequence of events including progressive loss of balance, psychosis, nystagmus, hyperreflexia and later, stupor. Her serum phenytoin level was found to exceed 40 mg/L. Her symptoms improved when phenytoin was switched to levetiracetam. Ours is the first case report of such an interaction in over 10 years and highlights the need to be extra-cautious while prescribing phenytoin and antitubercular therapy concomitantly, especially in a populations dominated by slow acetylators.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2024-262164DOI Listing

Publication Analysis

Top Keywords

antitubercular therapy
12
phenytoin
10
phenytoin toxicity
8
phenytoin antitubercular
8
toxicity caused
4
caused drug-to-drug
4
drug-to-drug interaction
4
interaction phenytoin
4
antitubercular
4
therapy phenytoin
4

Similar Publications

Phenytoin is one of the most used antiepileptic drugs. Isoniazid, a first-line antitubercular drug, blocks the CYP2C19 enzyme, preventing phenytoin from being metabolised. Concomitant use of phenytoin and isoniazid predisposes to phenytoin toxicity.

View Article and Find Full Text PDF

Background: When Behçet's disease is complicated with gastrointestinal ulcers, it is referred to as intestinal Behçet's disease (BD). Clinically uncommon, this condition can involve the entire gastrointestinal tract, often presenting diagnostic challenges in differentiation from Crohn's disease.

Methods: In this case, atypical BD was diagnosed through endoscopic examination, whereas latent tuberculosis infection (LBTI) was confirmed via T-SPOT and PPD tests.

View Article and Find Full Text PDF

Background: Globally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative bacteriological test result. There is limited information on the factors that determine clinicians' decisions to initiate TB treatment when initial bacteriological test results are negative.

Methods And Findings: We performed a systematic review and individual patient data meta-analysis using studies conducted between January 2010 and December 2022 (PROSPERO: CRD42022287613).

View Article and Find Full Text PDF

Intramedullary spinal tuberculomas constitute a small percentage of spinal tuberculosis. These, in combination with brain tuberculomas, are an uncommon manifestation of central nervous system (CNS) tuberculosis. This report details a unique case of a 32-year-old retroviral disease-positive male who presented with a two-month history of symmetrical quadriparesis and recent seizures.

View Article and Find Full Text PDF

Chemoprotective Mechanism of Sodium Thiosulfate Against Cisplatin-Induced Nephrotoxicity Is via Renal Hydrogen Sulfide, Arginine/cAMP and NO/cGMP Signaling Pathways.

Int J Mol Sci

January 2025

Department of Animal Experimentation, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra P.O. Box LG581, Ghana.

Cisplatin is a common and highly effective chemotherapeutic agent whose nephrotoxic side effect is well-characterized. Sodium thiosulfate (STS), an FDA-approved hydrogen sulfide (HS) donor drug, is emerging as a chemoprotective agent against cisplatin-induced nephrotoxicity (CIN). In this study, we investigated the chemoprotective mechanism of STS in a rat model of CIN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!